About Daniel Lynch
Daniel Lynch is a director and 10% owner at SpringWorks Therapeutics.
Form D filings name Daniel Lynch as a director at Cardurion Pharmaceuticals.
Daniel Lynch reports to the SEC as a director or major shareholder of 10 public companies, including 2seventy bio (TSVT), bluebird bio (BLUE) and Xilio Therapeutics (XLO).
Daniel Lynch first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name Daniel Lynch in the role, so the role may have started earlier or lasted longer.
SI
SpringWorks Therapeutics, Inc.
Director and 10% owner
2019 – 2025 · Public company (SWTX)
2I
2seventy bio, Inc.
Director
2021 – 2023 · Public company (TSVT)
BI
bluebird bio, Inc.
Director
2013 – 2021 · Public company (BLUE)
XI
Xilio Therapeutics, Inc.
Director and 10% owner
2021 · Public company (XLO)
TI
Translate Bio, Inc.
Director
2018 – 2021 · Public company (TBIO)
OS
Omega Alpha SPAC
Director
2021 · Public company (OMEG)
BC
Blueprint Medicines Corp
Director
2015 – 2020 · Public company (BPMC)
SI
Surface Oncology, Inc.
Director
2018 – 2020 · Public company (SURF)
CI
Carisma Therapeutics Inc.
Director
2014 – 2019 · Public company (CARM)
DI
Dnib Unwind, Inc.
Director
2013 – 2016 · Public company (BIND)
Key Colleagues at Startups
The people Daniel Lynch works with at each company, as listed on that company's latest Form D.
Cardurion Pharmaceuticals, Inc. · Form D, Jul 24, 2024
ER
Evan Rachlin
Director
Jeb Keiper
Director
MM
Michael Mendelsohn
Executive officer and director
ER
Emma Reeve
Director
PL
Peter Lawrence
President and Chief Executive Officer, director
EM
Edward Mathers
Director
AK
Adam Koppel
Director
ND
Nicholas Downing
Director